GlassScriptPhysician profile
Veronica H Vittitoe
NPI 1558108548
$783.03
in general payments reported to CMS, 2019-2025
18 companies · $783 in 2025
The $783 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $783.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $231.81 | 2025 | |
| Eisai INC. | $73.77 | 2025 | |
| Emd Serono, INC. | $72.02 | 2025 | |
| Neurocrine Biosciences, INC. | $56.54 | 2025 | |
| Genentech USA, INC. | $46.91 | 2025 | Ocrevus Zunovo |
| Amneal Pharmaceuticals LLC | $37.25 | 2025 | Crexont |
| Novartis Pharmaceuticals Corporation | $34.54 | 2025 | |
| Genzyme Corporation | $33.37 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $32.30 | 2025 | Austedo Xr |
| Janssen Biotech, INC. | $25.33 | 2025 | |
| Ucb, INC. | $20.58 | 2025 | Rystiggo |
| Acadia Pharmaceuticals INC | $19.05 | 2025 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $17.79 | 2025 | Rexulti |
| Lilly USA, LLC | $17.72 | 2025 | Kisunla |
| Ani Pharmaceuticals, INC. | $17.67 | 2025 | Purified Cortrophin Gel |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $16.41 | 2025 | |
| Axsome Therapeutics, INC. | $16.41 | 2025 | Symbravo |
| Biogen, INC. | $13.56 | 2025 | Vumerity, Tysabri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Vittitoe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.